therapeutically active agent may be associated with a container holding a flowable carrier component (e.g. a container may hold fibrinogen and C3).

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: LISA MCKERRACHER

(ii) TITLE OF INVENTION: Methods for making and delivering Rho-antangonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof

(iii) NUMBER OF SEQUENCES: 3

(iv) CORRESPONDENCE ADDRESS:
(A) ADRESSEE: BROULLETTE KOSIE
(B) STREET: 1100 RENE-LESVEQUE BLVD WEST
(C) PROV/STATE: QUEBEC
(D) COUNTRY: CANADA
(E) POSTAL/ZIP CODE: H3B 5C9

(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE:ASCII (TEXT)

(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:

(B) FILING DATE:

(C) CLASSIFICATION:

(vii) ATTORNEY/AGENT INFORMATION:

(A) NAME: RONALD S. KOSIE

(B) REGISTRATION NO.: 28,814

(C) REFERENCE/DOCKET NO.: 06447-003-US-2

(D) TEL. NO.: (514) 397 8500

(E) FAX NO.: (514) 397 8515

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS:

(D) TOPOLOGY:

(ii) MOLECULE TYPE:

(v) FRAGMENT TYPE:

(vi) ORIGINAL SOURCE:

(A) ORGANISM:

(vii) IMMEDIATE SOURCE:

(ix) FEATURE:

(A) NAME/KEY:

(B) LOCATION:

(D) OTHER INFORMATION:

(x) PUBLICATION INFORMATION:

(A) AUTHORS:

(B) TITLE:

(C) JOURNAL:

(D) VOLUME:

(E) ISSUE:

(F) PAGES:

(G) DATE:

(H) DOCUMENT NO.:

(I) FILING DATE:

(J) PUBLICATION DATE:

(K) RELEVANT RESIDUES IN SEQ ID NO:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GTG GCG ACC CTT CCC AAA TCG GAT CTG GTT CCG CGT GGA TCC TCT AGA
5 10 15

GTC GAC CTG CAG GCA TGC AAT GCT TAT TCC ATT AAT CAA AAG GCT TAT
20 25 30

TCA AAT ACT TAC CAG GAG TTT ACT AAT ATT GAT CAA GCA AAA GCT TGG
35 40 45

GGT AAT GCT CAG TAT AAA AAG TAT GGA CTA AGC AAA TCA GAA AAA GAA
50 55 60

GCT ATA GTA TCA TAT ACT AAA AGC GCT AGT GAA ATA AAT GGA AAG CTA
65 70 75 80

AGA CAA AAT AAG GGA GTT ATC AAT GGA TTT CCT TCA AAT TTA ATA AAA
85 90 95

CAA GTT GAA CTT TTA GAT AAA TCT TTT AAT AAA ATG AAG ACC CCT GAA

100 105 110

AAT ATT ATG TTA TTT AGA GGC GAC GAC CCT GCT TAT TTA GGA ACA GAA
115 120 125

TTT CAA AAC ACT CTT CTT AAT TCA AAT GGT ACA ATT AAT AAA ACG GCT
130 135 140

TTT GAA AAG GCT AAA GCT AAG TTT TTA AAT AAA GAT AGA CTT GAA TAT
145 150 155 160

GGA TAT ATT AGT ACT TCA TTA ATG AAT GTT TCT CAA TTT GCA GGA AGA
165 170 175

CCA ATT ATT ACA AAA TTT AAA GTA GCA AAA GGC TCA AAG GCA GGA TAT
180 185 190

ATT GAC CCT ATT AGT GCT TTT CAG GGA CAA CTT GAA ATG TTG CTT CCT
195 200 205

AGA CAT AGT ACT TAT CAT ATA GAC GAT ATG AGA TTG TCT TCT GAT GGT
210 215 220

AAA CAA ATA ATA ATT ACA GCA ACA ATG ATG GGC ACA GCT ATC AAT CCT
225 230 235 240

AAA TAA

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS:

(D) TOPOLOGY:

(vi) ORIGINAL SOURCE:

(A) ORGANISM:

(ix) FEATURE:

(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GGATCCTCTA GAGTCGACCT GCAGGCATGC AATGCTTATT CCATTAATCA 50
AAAGGCTTAT TCAAATACTT ACCAGGAGTT TACTAATATT GATCAAGCAA 100
AAGCTTGGGG TAATGCTCAG TATAAAAAGT ATGGACTAAG CAAATCAGAA 150
AAAGAAGCTA TAGTATCATA TACTAAAAGC GCTAGTGAAA TAAATGGAAA 200
GCTAAGACAA AATAAGGGAG TTATCAATGG ATTTCCTTCA AATTTAATAA 250
AACAAGTTGA ACTTTTAGAT AAATCTTTTA ATAAAATGAA GACCCCTGAA 300
AATATTATGT TATTTAGAGG CGACGACCCT GCTTATTTAG GAACAGAATT 350
TCAAAACACT CTTCTTAATT CAAATGGTAC AATTAATAAA ACGGCTTTTG 400
AAAAGGCTAA AGCTAAGTTT TTAAATAAAG ATAGACTTGA ATATGGATAT 450
ATTAGTACTT CATTAATGAA TGTTTCTCAA TTTGCAGGAA GACCAATTAT 500
TACAAAATTT AAAGTAGCAA AAGGCTCAAA GGCAGGATAT ATTGACCCTA 550
TTAGTGCTTT TCAGGGACAA CTTGAAATGT TGCTTCCTAG ACATAGTACT 600
TATCATATAG ACGATATGAG ATTGTCTTCT GATGGTAAAC AAATAATAAT 650
TACAGCAACA ATGATGGGCA CAGCTATCAA TCCTAAATAA

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:

(B) TYPE:

(C) STRANDEDNESS:

(D) TOPOLOGY:

(vi) ORIGINAL SOURCE:

(A) ORGANISM:

(ix) FEATURE:

(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GSSRVDLQAC NAYSINQKAY SNTYQEFTNI DQAKAWGNAQ YKKYGLSKSE 50

KEAIVSYTKS ASEINGKLRQ NKGVINGFPS NLIKQVELLD KSFNKMKTPE 100

NIMLFXGDDP AYLGTEFQNT LLNSNGTINK TAFEKAKAKF LNXDRLEYGY 150

ISTSLMNVSQ FAGRPIITKF KVAKGSKAGY IDPISAFQGQ LEMLLPRHST 200

YHIDDMRLSS DGKQIIITAT MMGTAINPK